Printer Friendly


 CAMBRIDGE, Mass., Oct. 21 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) will break ground today for its new $40 million, 150,000-square-foot research center at Twelve Cambridge Center in Cambridge, Mass.
 The new building, which will be completed in mid-1995, will triple Biogen's laboratory space. The start of the project is significant for the City of Cambridge because it is the largest new commercial construction project undertaken in the city in the last three years. The supervising public agency for the development of Cambridge Center is the Cambridge Redevelopment Authority. Biogen will own the building.
 Jim Vincent, Biogen's chairman and chief executive officer, said at the ground breaking that "Biogen is pleased to be putting up this building in Cambridge, which has been out home since our earliest years. However, our decision to build here was not automatic. Other communities with much to offer sought us out -- and several offers were very attractive. But we have our roots here and our employees enjoy living and working in Massachusetts. At the end of the day, our decision to build in Cambridge was the direct result of the efforts of a group of dedicated people in city and state government who worked hard to make it possible for us to remain and expand here."
 Edward H. Linde, president of Boston Properties, the developer of the site, said, "We have had the very good fortune to have worked with Biogen for over a decade and see them grow to be one of the most important, and, in our view, the best managed of all the biotech companies. We are delighted that Biogen has decided to make Cambridge Center its long-term home and look forward to working closely with them on the completion of this handsome new building, and in the future."
 Also speaking at the groundbreaking were Governor William Weld, Cambridge Mayor Ken Reeves, Secretary of Economic Affairs Gloria Larson and Jacqueline Sullivan, chair of the Cambridge Redevelopment Authority. Also present were members of the Cambridge City Council and other state and local dignitaries and representatives of Marshall Contractors of Rumford, R.I., the construction manager for the project and Payette Associates of Boston, the architect.
 Biogen, Inc., headquartered in Cambridge, is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS and other viruses and cancers.
 Boston Properties, Inc., is a national real estate development company with offices in Boston, New York City and Washington, D.C., specializing in the development and management of first class commercial properties. Founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde, it now owns and manages more than twelve million square feet of space and specializes in project and construction management and real estate marketing and finance.
 -0- 10/21/93
 /CONTACT: Kathryn R. Bloom, director of communications for Biogen, 617-252-9851; or Lloyd Wheeler or Sandy Caswell of Regan Communications, 617-742-8180, for Biogen/

CO: Biogen, Inc. ST: Massachusetts IN: MTC SU:

CM-JL -- NE009 -- 5219 10/21/93 12:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 21, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters